NYSE · AZN
AstraZeneca PLC
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for AZN has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $2.60 | $2.60 | $2.59 | 3 |
| Dec 2026 | $2.34 | $2.43 | $2.25 | 2 |
| Mar 2027 | $2.76 | $2.92 | $2.60 | 2 |
| Jun 2027 | $2.83 | $2.93 | $2.73 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel · MarketBeat- RTTNews · 1 h agoAstraZeneca Q3 Profit Rises; Pipeline Delivers 12 Positive Phase 3 Readouts; Stock Up(RTTNews) – AstraZeneca PLC (AZN) on Friday reported higher third-quarter profit and revenue, supported by growth across its major therapy areas. The company reaffirmed its full-year revenue and core earnings guidance while reporting progress across its clinical pipeline and laun
- RTTNews · 4 h agoAstraZeneca Q3 Profit Rises; Reconfirms FY26 Revenue, Core EPS Guidance At CER(RTTNews) – AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) reported that its third quarter profit attributable to owners of the Parent increased to $3.12 billion from $2.53 billion, prior year. Diluted earnings per $0.25 Ordinary Share was $2.00 compared to $1.62. Core EPS was $2.7
- Zacks · Oct 29, 11:06 AM EDTMRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock UpMerck's Q3 earnings and sales beat estimates as Keytruda and newer products drive growth, prompting the company to raise its 2026 earnings outlook.
- RTTNews · Oct 28, 3:02 AM EDTCardiff Names Alland Interim Medical Chief Ahead Of Planned Phase 3 Cancer Trial(RTTNews) – Shares of Cardiff Oncology, Inc. (CRDF) fell 5.70% in after-hours trading on Tuesday after the clinical-stage biotechnology company announced Leila Alland's appointment as interim chief medical officer (CMO).
- Fintel · Oct 27, 9:13 AM EDTAstraZeneca PLC Announces EU Approval of Enhertu for HER2-Positive Early Breast Cancer Following 53% Risk Reduction in Phase III TrialAstraZeneca PLC announced that Enhertu has been approved in the European Union as a monotherapy for the adjuvant treatment of adult patients with resected HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted treatment. Th
- Zacks · Oct 27, 7:56 AM EDTIs Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?MRK heads into Q3 earnings with strong Keytruda sales and new drug growth, but declining estimates, Gardasil weakness and looming patent risks cloud its outlook.
- RTTNews · Oct 27, 6:06 AM EDTAstraZeneca, Daiichi Sankyo's Enhertu Wins First EU Approval In Early Breast Cancer Setting(RTTNews) – On Tuesday, AstraZeneca (AZN) and Daiichi Sankyo (4568.T) said the European Commission approved Enhertu in the European Union, or EU as a standalone treatment after surgery for adults with HER2-positive breast cancer who have residual invasive disease following pre-su
- RTTNews · Oct 27, 5:40 AM EDTAstraZeneca Names Onco360 National Speciality Pharmacy Partner For Zegfrovy(RTTNews) – AstraZeneca (AZN) has selected Onco360 as a national speciality pharmacy partner for Zegfrovy (sunvozertinib), which is indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor rece
- RTTNews · Oct 27, 3:08 AM EDTAstraZeneca Projects $80 Bln In Total Revenue By 2030, Sustained Growth Beyond(RTTNews) – British drug major AstraZeneca Plc (AZN, AZN.L) announced that it aims for $80 billion in total revenue by 2030, and sustained growth beyond the year.
- MarketBeat · Oct 26, 9:02 PM EDTAstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor UpdateThe Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAstrazeneca (NYSE:AZN) highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the
- RTTNews · Oct 26, 7:44 AM EDTAstraZeneca's Sone-Ve Cuts Death Risk By 42% In Advanced Gastric Cancer Trial; Stock Up(RTTNews) – AstraZeneca (AZN) reported positive Phase 3 results showing that sonesitatug vedotin (Sone-Ve) significantly improved overall survival in patients with CLDN18.2-positive advanced gastric, gastroesophageal junction (GEJ) and oesophageal adenocarcinoma cancers treated i
- RTTNews · Oct 26, 7:30 AM EDTAstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up(RTTNews) – AstraZeneca (AZN) and HUTCHMED reported Phase 3 results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free and overall survival in patients with EGFR-mutated non-small cell lung cancer (NSCLC) whose disease
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for AstraZeneca PLC from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.